Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Design Therapeutics, Inc. - Common Stock (NQ:DSGN)

15.02 -0.01 (-0.07%)

Streaming Delayed Price Updated: 9:48 AM EDT, Sep 4, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	5,927
Open	14.96
Bid (Size)	14.91 (200)
Ask (Size)	15.12 (100)
Prev. Close	15.03
Today's Range	14.96 - 15.14
52wk Range	5.280 - 17.25
Shares Outstanding	55,945,551
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference

September 02, 2026

From Design Therapeutics, Inc.

Via GlobeNewswire

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

August 03, 2026

From Design Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+65.1%	+65.1%
1 Month	+13.8%	+13.8%
3 Month	+39.6%	+39.6%
6 Month	+48.9%	+48.9%
1 Year	+152.0%	+152.0%

More News

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

June 30, 2026

From Design Therapeutics, Inc.

Via GlobeNewswire

Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

May 28, 2026

From Design Therapeutics, Inc.

Via GlobeNewswire

What to Know About This Fund's $10 Million Bet on Gold Miners ↗

May 24, 2026

Via The Motley Fool

Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia

May 18, 2026

From Design Therapeutics, Inc.

Via GlobeNewswire

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026

May 17, 2026

From Design Therapeutics, Inc.

Via GlobeNewswire

Which stocks are moving on Wednesday? ↗

April 29, 2026

Via Chartmill

Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates

April 28, 2026

From Design Therapeutics, Inc.

Via GlobeNewswire

Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates

March 09, 2026

From Design Therapeutics, Inc.

Via GlobeNewswire

Design Therapeutics to Participate in Upcoming Investor Conferences

February 18, 2026

From Design Therapeutics, Inc.

Via GlobeNewswire

Design Therapeutics to Participate in Upcoming Investor Conferences

November 26, 2025

From Design Therapeutics, Inc.

Via GlobeNewswire

Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday ↗

November 20, 2025

Via Benzinga

Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results

November 05, 2025

From Design Therapeutics, Inc.

Via GlobeNewswire

Design Therapeutics Appoints Justin Gover to Board of Directors

September 10, 2025

From Design Therapeutics, Inc.

Via GlobeNewswire

Steven Cohen's Biotech Bets Are Getting Bolder — And Smaller ↗

August 29, 2025

Via Benzinga

Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

August 27, 2025

From Design Therapeutics, Inc.

Via GlobeNewswire

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results

August 07, 2025

From Design Therapeutics, Inc.

Via GlobeNewswire

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

June 04, 2025

From Design Therapeutics, Inc.

Via GlobeNewswire

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference

May 28, 2025

From Design Therapeutics, Inc.

Via GlobeNewswire

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

May 13, 2025

From Design Therapeutics, Inc.

Via GlobeNewswire

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

May 07, 2025

From Design Therapeutics, Inc.

Via GlobeNewswire

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

May 01, 2025

From Design Therapeutics, Inc.

Via GlobeNewswire

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

April 21, 2025

From Design Therapeutics, Inc.

Via GlobeNewswire

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

April 17, 2025

From Design Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Design Therapeutics, Inc. - Common Stock publicly traded?

Yes, Design Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Design Therapeutics, Inc. - Common Stock trade on?

Design Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Design Therapeutics, Inc. - Common Stock?

The ticker symbol for Design Therapeutics, Inc. - Common Stock is DSGN on the Nasdaq Stock Market

What is the current price of Design Therapeutics, Inc. - Common Stock?

The current price of Design Therapeutics, Inc. - Common Stock is 15.02

When was Design Therapeutics, Inc. - Common Stock last traded?

The last trade of Design Therapeutics, Inc. - Common Stock was at 09/04/26 09:48 AM ET

What is the market capitalization of Design Therapeutics, Inc. - Common Stock?

The market capitalization of Design Therapeutics, Inc. - Common Stock is 840.30M

How many shares of Design Therapeutics, Inc. - Common Stock are outstanding?

Design Therapeutics, Inc. - Common Stock has 840M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.